Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
22 févr. 2023 07h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on...
Myriad Genetics to Participate in Upcoming Healthcare Conferences
09 févr. 2023 07h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the...
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
07 févr. 2023 07h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that...
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
05 janv. 2023 07h05 HE
|
Myriad Genetics, Inc.
Myriad Genetics continues to advance non-invasive prenatal screening with Prequel® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) --...
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief...
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
19 déc. 2022 16h05 HE
|
Myriad Genetics, Inc.
New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
08 déc. 2022 19h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study...
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
29 nov. 2022 16h05 HE
|
Myriad Genetics, Inc.
Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics,...
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
17 nov. 2022 07h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can...
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
14 nov. 2022 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and...